Payment overview · 2025
General Payments
$447.36
24 reported records · 12 companies
Healthcare provider profile · identity verified
Norman A Schwartz, MD
Allopathic & Osteopathic Physicians|Family Medicine · PATASKALA, OH · NPI 1255322335
Verified facts
What the public records show
CMS Open Payments records show Norman A Schwartz, MD received $447.36 in general payments during 2025 across 24 reported records.
Sumitomo Pharma America, Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $109.20 | 24.4% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $62.64 | 14.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.64 | 14.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.91 | 11.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.47 | 7.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.57 | 7.5% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $17.44 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.35 | 3.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.97 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.96 | 3.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.50 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.71 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $447.36 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $109.20 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $62.64 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $62.64 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 27 |
| Alprazolam | Alprazolam | 127 | 16 |
| Gabapentin | Gabapentin | 127 | 24 |
| Carvedilol | Carvedilol | 125 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 27 |
| Omeprazole | Omeprazole | 111 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 106 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 35 |
| Clonazepam | Clonazepam | 99 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 19 |
| Metformin Hcl | Metformin Hcl | 67 | 21 |
| Furosemide | Furosemide | 65 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 60 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 59 | 18 |
| Lisinopril | Lisinopril | 57 | 17 |
| Losartan Potassium | Losartan Potassium | 56 | 16 |
| Prednisone | Prednisone | 55 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 51 | 16 |
| Nystatin | Nystatin | 50 | 12 |
| Tramadol Hcl | Tramadol Hcl | 48 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 47 | 21 |
| Eliquis | Apixaban | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 15 |
| Finasteride | Finasteride | 43 | 15 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 12 |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 14 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Lactulose | Lactulose | 35 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Minoxidil | Minoxidil | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 26 | 14 |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 14 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Constulose | Lactulose | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Jardiance | Empagliflozin | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $447.36 · 24 records | Sumitomo Pharma America, Inc. | AIRSUPRA, CAPLYTA, FREESTYLE LIBRE 3, GEMTESA, KEVEYIS, KISUNLA, Kerendia, Ohtuvayre, REXULTI, SUBLOCADE, VERQUVO, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error